2 days Ago
NEW DELHI: Activists in India are opposing US pharmaceutical major Gilead Sciences ' patent applications on HIV prevention drug lenacapavir , in a bid to make the ground-breaking treatment affordable for all. Lenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears Gilead's patent applications, generic drug makers in India will not be allowed to produce its affordable forms.
This week, the patent office is likely to hear the objections of Sankalp Rehabilitation Trust--a civil society organisation which works with people vulnerable to HIV- to Gilead's patent applications regarding lenacapavir which, if granted, will extend the company's monopoly over lenacapavir. Gilead has several patent applications in India on lenacapavir. Two of these applications, filed in 2020, seek patents on the choline and sodium salt of the drug lenacapavir.
Sankalp contends that Gilead's claims on the salt forms of lenacapavir are not innovative. It had opposed Gilead's patent applications in 2021 on the ground that the drug has a previously known compound. Indian patent law prohibits "evergreening", a practice by which pharmaceutical companies seek patents on routine modifications to extend their drug monopolies beyond the standard 20-year period.
Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Basics of Generative AI : Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Finance Financial Literacy - TDS, Budget, Income Tax Act, GST, Indirect tax By - CA Rahul Gupta, CA with 10+ years of domain experience, trainer View Program Leadership Business Storytelling Masterclass By - Ameen Haque, Founder of Storywallahs View Program Future of Marketing & Branding Masterclass By - Dr. David Aaker, Professor at Haas School of Business View Program HR & People Management Human Potential and the Future of Employment By - Lynda Gratton, Co-chair of the World Economic Forum Council on Work, Wages and Job Creation, Professor of Management Practice View Program Strategy ESG and Business Sustainability Strategy By - Vipul Arora, Partner, ESG & Climate Solutions at Sattva Consulting Author I Speaker I Thought Leader View Program Finance Financial Reporting and Analytics By - Dr.
C.P. Gupta, Professor: Department of Finance and Business Economics, University of Delhi View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program "Granting these patents, which would last until August 2038, could hinder access to affordable generic versions of lenacapavir," Eldred Tellis , director of Sankalp Rehabilitation Trust , said in a statement.
"Affordable generic HIV medicines have been crucial in keeping people alive globally, including in India." Lenacapavir is administered as twice-yearly injections and has garnered attention for its potential in HIV prevention after multiple clinical trials demonstrated superior efficacy to standard oral preventative medicines, known as pre-exposure prophylaxis (PrEP). According to UNAIDS, the new HIV drug can play a crucial role in ending AIDS if all have access.
(You can now subscribe to our Economic Times WhatsApp channel ).
